Clinical trial
A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
NCT01643850 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 23, 2012
- Completion date
- December 21, 2018
- Enrollment
- 36 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
gccts, gcts, giant cell tumor of the tendon sheath, pigmented villonodular synovitis, pvns, tenosynovial giant cell tumor localized or diffused type